A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers

Sponsor

Tmunity Therapeutics (Industry)

Overall Status

Active, not recruiting

CT.gov ID

NCT04025216

Collaborator

(none)

112

Enrollment

Locations

Arms

204.7

Anticipated Duration (Months)

11.2

Patients Per Site

0.1

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Multi-center, open-label, first in human Phase 1 study of the safety, tolerability, feasibility, and preliminary efficacy of the administration of genetically modified autologous T cells (CART-TnMUC1 cells) engineered to express a chimeric antigen receptor (CAR) capable of recognizing the tumor antigen, TnMUC1 and activating the T cell (CART- TnMUC1 cells).

Condition or Disease	Intervention/Treatment	Phase
Non-Small Cell Lung Cancer Ovarian Cancer Fallopian Tube Cancer Triple Negative Breast Cancer Multiple Myeloma Pancreatic Ductal Adenocarcinoma	Biological: CART-TnMUC1 Drug: Cyclophosphamide Drug: Fludarabine	Phase 1

Detailed Description

The Dose Escalation phase of the study is designed to identify the dose and regimen of CART-TnMUC1 cells that can be safely administered intravenously following the lymphodepletion (LD) regimen to patients with (1) advanced TnMUC1+ solid tumors (triple negative breast cancer, epithelial ovarian cancer, pancreatic cancer, and non-small cell lung cancer) and (2) advanced TnMUC1+ multiple myeloma in a parallel two-arm dose escalation study. The Dose Escalation phase is anticipated to enroll approximately 40 patients.

The Expansion phase of the study is designed to assess the preliminary efficacy of CART-TnMUC1 cells administered intravenously to patients with TnMUC1+ solid tumors. The Expansion phase is anticipated to enroll approximately 72 patients (18 patients per each tumor indication).

Study Design

Study Type:

Interventional

Anticipated Enrollment :

112 participants

Allocation:

Non-Randomized

Intervention Model:

Sequential Assignment

Intervention Model Description:

Parallel arms with sequential dose escalationParallel arms with sequential dose escalation

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

A Phase 1 Open-Label, Multi-Center First in Human Study of TnMUC1-Targeted Genetically-Modified Chimeric Antigen Receptor T Cells in Patients With Advanced TnMUC1-Positive Solid Tumors and Multiple Myeloma

Actual Study Start Date :

Oct 10, 2019

Anticipated Primary Completion Date :

Dec 31, 2022

Anticipated Study Completion Date :

Oct 31, 2036

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Dose Escalation Arm1: Solid Tumors Intravenous CART-TnMUC1 cells for patients with TnMUC1+ treatment-resistant ovarian cancer (including cancers of the fallopian tube), pancreatic ductal adenocarcinoma, hormone receptor (HR)-negative and human epidermal growth factor receptor 2 (HER2)-negative (triple negative) breast cancer and non-small cell lung cancer	Biological: CART-TnMUC1 Single intravenous administration of genetically modified autologous T cells engineered to express a TnMUC1-Targeted Genetically-Modified Chimeric Antigen (CAR) Drug: Cyclophosphamide Patients will receive cyclophosphamide and fludarabine lymphodepletion chemotherapy followed by the investigational product, CART-TnMUC1 Drug: Fludarabine Patients will receive cyclophosphamide and fludarabine lymphodepletion chemotherapy followed by the investigational product, CART-TnMUC1
Experimental: Dose Escalation Arm 2: Multiple Myeloma Intravenous CART-TnMUC1 cells for patients with TnMUC1+ relapsed/refractory multiple myeloma	Biological: CART-TnMUC1 Single intravenous administration of genetically modified autologous T cells engineered to express a TnMUC1-Targeted Genetically-Modified Chimeric Antigen (CAR) Drug: Cyclophosphamide Patients will receive cyclophosphamide and fludarabine lymphodepletion chemotherapy followed by the investigational product, CART-TnMUC1 Drug: Fludarabine Patients will receive cyclophosphamide and fludarabine lymphodepletion chemotherapy followed by the investigational product, CART-TnMUC1

Arm

Intervention/Treatment

Experimental: Dose Escalation Arm1: Solid Tumors

Intravenous CART-TnMUC1 cells for patients with TnMUC1+ treatment-resistant ovarian cancer (including cancers of the fallopian tube), pancreatic ductal adenocarcinoma, hormone receptor (HR)-negative and human epidermal growth factor receptor 2 (HER2)-negative (triple negative) breast cancer and non-small cell lung cancer

Biological: CART-TnMUC1

Single intravenous administration of genetically modified autologous T cells engineered to express a TnMUC1-Targeted Genetically-Modified Chimeric Antigen (CAR)

Drug: Cyclophosphamide

Patients will receive cyclophosphamide and fludarabine lymphodepletion chemotherapy followed by the investigational product, CART-TnMUC1

Drug: Fludarabine

Patients will receive cyclophosphamide and fludarabine lymphodepletion chemotherapy followed by the investigational product, CART-TnMUC1

Experimental: Dose Escalation Arm 2: Multiple Myeloma

Intravenous CART-TnMUC1 cells for patients with TnMUC1+ relapsed/refractory multiple myeloma

Biological: CART-TnMUC1

Single intravenous administration of genetically modified autologous T cells engineered to express a TnMUC1-Targeted Genetically-Modified Chimeric Antigen (CAR)

Drug: Cyclophosphamide

Patients will receive cyclophosphamide and fludarabine lymphodepletion chemotherapy followed by the investigational product, CART-TnMUC1

Drug: Fludarabine

Patients will receive cyclophosphamide and fludarabine lymphodepletion chemotherapy followed by the investigational product, CART-TnMUC1

Outcome Measures

Primary Outcome Measures

Dose Escalation: Dose Identification of CART-TnMUC1 [Up to 2 years]
Incidence of Dose Limiting Toxicity (DLT) in solid tumors and multiple myeloma
Cohort Expansion: Objective Response in solid tumors [Up to 2 years]
Proportion of patients having a confirmed Complete Response (CR) or Partial Response (PR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1

Secondary Outcome Measures

Safety of CART-TnMUC1 in solid tumors and multiple myeloma [Up to 2 years]
Percentage of patients experiencing adverse events (AEs), including serious and severe AEs overall, by dose level, and by severity Grade
Tolerability of CART-TnMUC1 in solid tumors and multiple myeloma [Up to 2 years]
Frequency of treatment emergent AEs, frequency of clinical changes from baseline in vital signs, changes in electrocardiogram, and hematology and chemistry laboratory shifts from baseline
Feasibility of CART-TnMUC1 in solid tumors and multiple myeloma [Up to 2 years]
Proportion of enrolled patients who did not receive CART-TnMUC1 cells
Preliminary anti-tumor efficacy of CART as assessed by Overall Survival (OS) in solid tumors and multiple myeloma [Up to 2 years]
OS as defined by the interval between CART-TnMUC1 cell infusion and date of death by any cause
Preliminary anti-tumor efficacy of CART as assessed by Progression Free Survival (PFS) in solid tumors [Up to 2 years]
PFS as defined by the interval between CART-TnMUC1 cell infusion and date of disease progression by RECIST v1.1 or death in solid tumors and by International Myeloma Working Group (IMWG) criteria in multiple myeloma
Preliminary anti-tumor efficacy of CART as assessed by Objective Response Rate (ORR) in solid tumors and multiple myeloma [Up to 2 years]
Proportion of patients having a confirmed CR or PR per RECIST v1.1 in solid tumors and IMWG criteria (PR, Very Good PR, CR, Stringent CR) in multiple myeloma
Preliminary anti-tumor efficacy of CART as assessed by Clinical Benefit Rate in solid tumors [Up to 2 years]
Proportion of patients having a confirmed CR, PR, or Stable Disease (SD) per RECIST v1.1
Preliminary anti-tumor efficacy of CART as assessed by Duration of Response (DOR) in solid tumors and multiple myeloma [Up to 2 years]
DOR as defined by the interval of first documented response until first documented disease progression or death in solid tumors and multiple myeloma
Preliminary anti-tumor efficacy of CART as assessed by Time to Response (TTR) in solid tumors and multiple myeloma [Up to 2 years]
Time to Response as defined by the interval between CART-TnMUC1 cell infusion and first documented CR or PR per RECIST v1.1 in solid tumors and IMWG criteria in multiple myeloma
Preliminary anti-tumor efficacy of CART as assessed by Time to Progression (TTP) in multiple myeloma [Up to 2 years]
Time to Progression as defined by the interval between CART-TnMUC1 cell infusion and first documented progression or death due to disease per RECIST v1.1 in solid tumors and IMWG criteria in multiple myeloma
Preliminary anti-tumor efficacy of CART as assessed by Minimal Residual Disease (MRD) in multiple myeloma [Up to 2 years]
Defined by MRD-negative rate per IMWG criteria
Peripheral expansion and persistence of CART-TnMUC1 cells in solid tumors and multiple myeloma [Up to 15 years]
Defined as quantitative polymerase chain reaction (qPCR) documenting loss of CART cells

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Key Inclusion Criteria:

Confirmed diagnosis of metastatic treatment-resistant ovarian cancer (including cancers of the fallopian tube), pancreatic adenocarcinoma, hormone receptor (HR)-negative and HER2-negative (triple negative) breast cancer (TNBC) or non-small cell lung cancer (NSCLC), or relapsed/refractory multiple myeloma
Eastern Cooperative Oncology Group (ECOG) score of 0 or 1
Prior therapies as defined by tumor type:
Multiple myeloma: relapsed or refractory disease previously treated with or intolerant to at least three different lines of therapy that contained at least one of the following drug classes: proteasome inhibitor, an immune modulatory drug, alkylators, CD38 monoclonal antibody and glucocorticoids. Patients must be at least 90 days since autologous stem cell transplant
NSCLC: i.) Patients without driver mutations must have received standard therapy, including both checkpoint inhibition and platinum-based chemotherapy or be intolerant of these standard therapies ii.) Patients with driver mutations must have received or be intolerant to prior targeted therapy directed at the specific identified mutations in addition to the standard chemotherapy classes
Pancreatic adenocarcinoma: disease progression following at least one standard of care systemic chemotherapy for metastatic or unresectable disease or be intolerant of these standard therapies
TNBC: ER and/or PR < or =10%, HER2 negative and experienced disease progression following at least one prior systemic anti-cancer therapy regimen as part of their treatment for management of metastatic breast cancer or be intolerant to these standard therapies
Ovarian: platinum-resistant (progression of disease by either CA-125, clinical or radiographic assessment within 6 months of last platinum-based chemotherapy ) and must have received at least two prior lines of therapy for metastatic ovarian cancer, including at least one prior line of therapy including a platinum-containing regimen or be intolerant of these standard therapies
Evaluable disease as defined by tumor type
TnMUC1+ disease, determined by centrally tested TnMUC1 expression in a prior or archival tumor biopsy
Toxicities from any previous therapy must have recovered to Grade 1 or baseline
Estimated estimated glomerular filtration rate ≥ 60 m/min by Modification of Diet in Renal Disease criteria
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≤ 2.5 x upper institutional limit of normal with the following exception: Patients with known hepatic metastases, AST or ALT ≤ 3 x upper institutional limit of normal
Serum total bilirubin < 1.5 mg/dL with the following exception: patients with known Gilbert's disease, serum total bilirubin < 3 mg/dL
Serum albumin ≥ 3.0 g/dL (solid tumor patients in Arm 1 and Phase 1a only, not applicable to patients with multiple myeloma)
Left ventricular ejection fraction (LVEF) ≥ 50%. LVEF assessment must have been performed within 6 months of treatment start
Hemoglobin ≥ 8 g/dL
Absolute neutrophil count ≥ 1000/μL
Platelet count ≥ 75,000/μL (for Multiple Myeloma patients with bone marrow plasma cells ≥ 50% of cellularity: ≥ 30,000/μL)
Patients of reproductive potential agree to use approved contraceptive methods per protocol

Key Exclusion Criteria:

Active invasive cancer other than the proposed cancers included in the study
Current treatment with systemic high-dose corticosteroids (defined as a dose greater than the equivalent of prednisone 10 mg/day)
Active autoimmune disease (including connective tissue disease, uveitis, sarcoidosis, inflammatory bowel disease or multiple sclerosis) or have a history of severe autoimmune disease requiring prolonged immunosuppressive therapy (any immunosuppressive therapy should have been stopped within 6 weeks prior to screening visit)
Current human immunodeficiency virus (HIV), hepatitis C virus (HCV), hepatitis B virus (HBV) infections
Other active or uncontrolled medical or psychiatric condition that would preclude participation in the opinion of the Sponsor or Principal Investigator
Prior allogeneic stem cell transplant
Active and untreated central nervous system (CNS) malignancy
History of severe infusion reaction to monoclonal antibodies or biological therapies, or to study product excipients that would preclude the patient safely receiving CART-TnMUC1 cells
Active or recent (within the past 6 months prior to apheresis) cardiovascular disease, defined as (1) New York Heart Association (NYHA) Class III or IV heart failure, (2) unstable angina or (3) a history of recent (within 6 months) myocardial infarction or sustained (> 30 second) ventricular tachyarrhythmias, or (4) cerebrovascular accident
Have inadequate venous access for or contraindications for the apheresis procedure
Pregnant or breastfeeding women

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Mayo Clinic of Arizona	Phoenix	Arizona	United States	85054
2	The Angeles Clinic and Research Institute	Los Angeles	California	United States	90025
3	Moffitt Cancer Center	Tampa	Florida	United States	33637
4	University of Chicago Medical Center	Chicago	Illinois	United States	60637
5	Washington University School of Medicine	Saint Louis	Missouri	United States	63110
6	Hospital of the University of Pennsylvania	Philadelphia	Pennsylvania	United States	19104
7	University of Pittsburgh Medical Center	Pittsburgh	Pennsylvania	United States	15232
8	Sarah Cannon Research Institute	Nashville	Tennessee	United States	37203
9	The University of Texas MD Anderson Cancer Center	Houston	Texas	United States	77030
10	University of Washington Medical Center	Seattle	Washington	United States	98195